Drug news
NICE rejects Revlimid for Multiple Myeloma post Velcade - Celgene
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Revlimid (lenalidomide) from Celgene, for people whose Multiple Myeloma has relapsed once after receiving one treatment with Velcade (bortezomib) from Janssen Cilag, and are unable to receive thalidomide and for whom bone marrow transplantation is not appropriate.
In 2009 NICE approved use of Revlimid in patients who have received two or more prior therapies, and this guidance still stands.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins